At the news
? NEUTRALIMPACT 5/10 PRESS-RELEASE filed Mar 17, 2026 at 16:30 ET
Immunocore announced it will present five-year overall survival data from the KIMMTRAK Phase 3 trial in metastatic uveal melanoma at the 2026 AACR Annual Meeting. This represents the longest OS follow-up in a randomized trial for this patient population, potentially reinforcing KIMMTRAK's clinical benefit in a rare and aggressive cancer with limited treatment options.
- Immunocore will present five-year overall survival data from the KIMMTRAK Phase 3 trial at AACR 2026.
- Data comes from a randomized trial in HLA-A*02:01-positive patients with previously untreated metastatic uveal melanoma.
- Presentation includes additional insights: subsequent treatments, treatment beyond progression, and prognostic factors.
- KIMMTRAK is already approved in the U.S., EU, Canada, Australia, and the UK for this indication.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access